Alira Health

We're excited to attend HBI 2025! Take this opportunity to connect with our experts on-site and discover how we can help you achieve your strategic objectives while maximizing the value of your investments—whether through identifying high-value opportunities, conducting due diligence, or optimizing portfolio performance.?Meet our delegates: Dr. Michal Raciborski and Marc Nomaksteinsky. Healthcare Business International #HBI2025

A global pharmaceutical company specializing in rare cholestatic liver diseases partnered with us to map the patient journey and develop targeted engagement strategies. Read the full case study: https://lnkd.in/gpzjt5VT Our patient engagement team conducted a multi-country analysis, combining primary and secondary research to: ?? Identify unmet needs, pain points, and best clinical practices across geographies ?? Segment patients based on behavioral insights, including disease acceptance and attitudes toward physicians ?? Develop a patient-centric value proposition aligned with real-world patient experiences These insights empowered the client to refine their patient engagement, advocacy, and physician outreach strategies.

In his latest article, Akash Karopadi explores the evolving heart failure medical devices market and the key trends shaping its future. Read the full article: https://lnkd.in/gbN2nUyc Valued at ~$6 billion in 2024, this market is set for significant growth, driven by an aging population, rising obesity rates, and continuous medical advancements. Key insights from the article: ?? Demographic shifts and pharmaceutical advancements are fueling expansion. ?? Miniaturized circulatory support devices, digital health solutions, and weight loss drugs are transforming heart failure care. ?? Reimbursement hurdles, specialist shortages, and financial pressures on hospitals remain key obstacles.

Hello from Milan at BIO-Europe Spring 2025! Thanks to everyone who connected with our delegates on-site and discussed how can we support your planning, funding, and executing processes both strategically and technically. Benjamin Chambon, Joris Pezzini, Marc Nomaksteinsky, Tabatha Bourgois, Shaneze CHEBBAH. #BIOEuropeSpring EBD Group

Pharmaceutical companies carefully plan their launch strategies to balance market access and pricing regulations, but do launches in emerging markets affect drug prices in developed countries? Our analysis of two oncology drugs, Tecentriq and Imfinzi, reveals key insights into: ?? Launch sequencing trends in developed vs. emerging markets ?? Post-launch pricing dynamics from 2016 to 2024 ?? The role of External Reference Pricing Click right to explore the data from our experts: Clara Bordoy Coma-Cros, Charlotte Stasse, Esther Vidiella Caelles, Irene Lizano, PhD, and Nerea Blanque Catalina.

Read expert insights on five key methodologies beyond patient advisory boards, including discrete choice experiments, ethnographic studies, and multistakeholder workshops that can enhance patient engagement strategies and inform decision-making. Read the full article: https://lnkd.in/gVEFbQ_D Patient advisory boards are a go-to method for gathering patient perspectives, offering a structured approach in which patients provide their perspectives and feedback on treatments, clinical trials, healthcare policies, and other topics. However, depending on the nature of the input needed, other approaches may also provide deep, and actionable insights. Connect with our patient engagement experts to learn more about methodologies to gather patient insights: Eduardo Perez-Guagnelli and Giulia Pierini.

In this FAQ, our patient engagement experts, Annabel de Maria Bosch and Giulia Pierini, answer key questions about making patient engagement the core of your strategy. Click right to get answers to: ?? What are the benefits of developing a patient-centric strategy for your product? ?? How is a product developed with a patient-centric strategy mutually beneficial for patients and the industry? ?? Where should you start if you want to develop a robust patient-centric strategy?

How can biotech companies reshape their strategies to bring life-changing treatments to rare disease patients? In this interview, Joris Pezzini shares insights on why traditional drug development models often fall short in the rare disease field, and how an integrated, patient-access-driven approach can lead to success. Click right to read the full interview.

We’re looking forward to attending German Biotech Days 2025! As proud members of BIO Deutschland e. V., with a strong presence in Germany, we are committed to advancing biotech innovation locally and globally. We guide biotechs through the complexities of drug development, breaking down the process into clear, achievable value inflection points. Meet our team on-site to explore how we can help turn medical value creation into measurable ROI. Contact us to set up a meeting: https://lnkd.in/gD6Fs3Vr Connect with our delegates ahead of the event: Christian Hughes and Svetlana Fedorycheva. #DBT2025

What are key areas driving the growing importance of patient engagement in life sciences? Click right to discover them. The healthcare industry is evolving, and patient engagement is becoming a strategic priority for life sciences companies: ??Regulatory agencies and market access frameworks are driving this shift, as organizations like the Food and Drug Administration and the European Medicines Agency introduce new guidelines that foster patient involvement in drug and medical device development. ??At the same time, real-world evidence is playing an increasingly important role in regulatory and reimbursement decisions, encouraging companies to collect meaningful patient data throughout the product lifecycle to support approvals, pricing, and market access.